## Abstract ## Objective Health care providers in juvenile idiopathic arthritis (JIA) might refer to caregivers' self‐report of children's treatment‐related behaviors to assist in clinical decisions. However, caregivers may believe that they are adhering to treatment even though they have a differ
Mizoribine in the treatment of rheumatoid arthritis and juvenile idiopathic arthritis
✍ Scribed by Syuji Takei
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 90 KB
- Volume
- 44
- Category
- Article
- ISSN
- 1328-8067
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background: Mizoribine (MZR), isolated from culture medium of the mold, is a novel immunosuppressant developed in Japan. It has been used in patients with renal transplantation, lupus nephritis, nephrotic syndrome and rheumatoid arthritis (RA).
Objectives: To review MZR in regards to mechanism of action, pharmacokinetics, efficacy and safety in the treatment of rheumatoid RA and juvenile idiopathic arthritis (JIA).
Results: The drug MZR inhibits both humoral and cellular immunity in RA patients. It is completely excreted in the urine within 24 h, which contributes to the safety of MZR. A series of multicenter studies indicated that MZR was effective and safe in the treatment of RA. In JIA, however, there are only a few case reports reporting its efficacy and safety.
Conclusion: A double‐blinded multicenter study is needed to establish the efficacy, safety and indication of MZR in the treatment of JIA.
📜 SIMILAR VOLUMES
## Abstract With initial hopes of establishing a diagnostic test for juvenile rheumatoid arthritis (JRA), five types of immunoadsorbents were used to search for occult antiglobulins in sera from children. The immunoadsorbents included glutaraldehyde‐aggregated globulin, heat‐ and glutaraldehyde‐agg